NCT07120698 (CTONG 2508) is a Phase 2 clinical trial of Sintilimab in NSCLC (Non-small Cell Lung Cancer), sponsored by Guangdong Association of Clinical Trials.

Who is sponsoring NCT07120698?

NCT07120698 is sponsored by Guangdong Association of Clinical Trials.

What drugs are being tested in NCT07120698?

Interventions in NCT07120698: Sintilimab.

What condition does NCT07120698 study?

NCT07120698 studies NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy.

Is NCT07120698 still recruiting?

NCT07120698 is currently recruiting now. Last updated 5 January 2026.

Last reviewed 2026-01-05 · How we verify

NCT07120698: CTONG 2508

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)

Recruiting now Phase 2 Last updated 5 January 2026

What this trial tests

Phase 2 trial testing Sintilimab in NSCLC (Non-small Cell Lung Cancer) in 115 participants. Currently enrolling.

Timeline

5 November 2025

Primary endpoint
26 June 2029

26 July 2029

Quick facts

Lead sponsor	Guangdong Association of Clinical Trials
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	115
Start date	5 November 2025
Primary completion	26 June 2029
Estimated completion	26 July 2029
Sites	2 locations across China

Drugs / interventions tested

Sintilimab — full drug profile →

Conditions studied

NSCLC (Non-small Cell Lung Cancer) — all drugs for NSCLC (Non-small Cell Lung Cancer) →
MRD — all drugs for MRD →
II-IIIB Stages — all drugs for II-IIIB Stages →
Adjuvant Immunotherapy — all drugs for Adjuvant Immunotherapy →

Sponsor

Guangdong Association of Clinical Trials

Who can join

Adults 28 to 75, any sex, with NSCLC (Non-small Cell Lung Cancer) or MRD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung cancer (NSCLC) who have not achieved a pathological complete response (non-pCR) after neoadjuvant immunotherapy combined with chemotherapy. The study is being conducted at the Third People's Hospital of Chengdu and the Guangdong Provincial People's Hospital.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sintilimab

Trials testing the same drug.

NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting

Other recruiting trials for NSCLC (Non-small Cell Lung Cancer)

Currently open trials in the same condition.

NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07354061 — Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
NCT07122258 — Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1 · NA · recruiting
NCT07441941 — Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup · recruiting
NCT07330050 — WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC · Phase 2 · recruiting

Other Guangdong Association of Clinical Trials trials

Trials by the same sponsor.

NCT07412262 — A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment · Phase 2 · not yet recruiting
NCT07416058 — PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC · Phase 2 · not yet recruiting
NCT07375316 — A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC · Phase 2 · recruiting
NCT07198620 — A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China · not yet recruiting
NCT06282874 — Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07120698 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Association of Clinical Trials
Last refreshed: 5 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07120698.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing